Katsi Vasiliki K, Michalakeas Christos A, Grassos Charalambos E, Vamvakou Georgia D, Lekakis John P, Tousoulis Dimitris, Stefanadis Christodoulos I, Makris Thomas K, Kallikazaros Ioannis E
Cardiology Department, Hippocratio Hospital, Greece, Vas. Sofias Avenue 114, Post code: 11527, Athens, Greece.
Recent Pat Cardiovasc Drug Discov. 2013 Dec;8(3):216-20. doi: 10.2174/1574890108666131213100613.
Canagliflozin-with the patent number WO2011142478A1- belongs to a novel class of antidiabetic drugs known as SGLT2 inhibitors, which has been approved by FDA in March 2013. This medication acts through the inhibition of glucose reabsorption in the kidney resulting in glucosuria and thus lowering of glucose blood levels. There are several phase III clinical ongoing trials involving this new class of medications. So far promising results have been shown. This review article summarizes current knowledge regarding the novel SGLT2 inhibitor canagliflozin and its future perspectives in the treatment of type 2 diabetes mellitus.
卡格列净（专利号WO2011142478A1）属于一类新型抗糖尿病药物，即钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂，于2013年3月获美国食品药品监督管理局（FDA）批准。该药物通过抑制肾脏对葡萄糖的重吸收起作用，导致糖尿，从而降低血糖水平。目前有多项涉及这类新型药物的III期临床试验正在进行。到目前为止，已显示出有前景的结果。这篇综述文章总结了关于新型SGLT2抑制剂卡格列净的现有知识及其在2型糖尿病治疗中的未来前景。
